FDA advisory committee thumbs down on Biogen Alzheimer's candidate aducanumab

• The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 (2 uncertain) that the Phase 3 EMERGE study (the one that was successful at the higher dose) evaluating Biogen's (NASDAQ:BIIB) aducanumab in patients with mild Alzheimer's disease was not enough to demonstrate efficacy.
• The sister study, ENGAGE, failed.
• Shares will be poised for a significant drop when trading resumes.
• https://seekingalpha.com/news/3633299-fda-advisory-committee-thumbs-down-on-biogen-alzheimers-candidate-aducanumab